Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stromal vascular fraction cells (BHI Therapeutic Sciences)
- Development stage
- Unknown
- Lead developer
- BHI Therapeutic Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intravenous
01
Overview
Stromal vascular fraction (SVF) cell therapy, developed by BHI Therapeutic Sciences, is an autologous cell-based treatment derived from adipose tissue. SVF is obtained through enzymatic digestion of fat and consists of a heterogeneous population of cells, including mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells, and progenitor cells. The therapy functions through multiple mechanisms, including the modulation of inflammation, neuroprotection, angiogenesis, and immunomodulation. Specifically, MSCs within the SVF release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) to support tissue repair and paracrine signaling. BHI Therapeutic Sciences utilizes SVF across more than 50 treatment protocols for conditions ranging from orthopedic disorders like osteoarthritis to autoimmune diseases (e.g., multiple sclerosis, lupus) and neurological conditions (e.g., ALS, Parkinson's disease).
- Other names
- SVFAdipose-derived stromal vascular fractionAdipose SVF
Beyond the preview
Go deeper on stromal vascular fraction cells (BHI Therapeutic Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stromal vascular fraction cells (BHI Therapeutic Sciences).